-
Ariceum develops satoreotide its first and best-in-class somatostatin receptor 2 antagonist in intensive stage small cell lung most cancers
-
Phase Ib research design will likely be introduced on the European Association of Nuclear Medicine Congress 2023 (EANM 2023) in Vienna, Austria on 10th September 2023
BERLIN, Sept. 7, 2023 /PRNewswire/ — Ariceum Therapeutics (Ariceum), a personal biotech firm growing radiopharmaceutical merchandise for the prognosis and therapy of sure hard-to-treat cancers, is happy to announce that the primary affected person has been dosed with its first-in-class lead molecule, satoreotide, focusing on intensive stage small cell lung most cancers (ES-SCLC), on the Murdoch University Health Center in Perth, Australia.
Ariceum has efficiently initiated its multicentre, open label Phase Ib research which is able to examine the protection and tolerability of the ‘theranostic pair’ of somatostatin receptor antagonist 68Ga-Satoreotide Trizoxetan (SSO120) and 177Lu-satoreotide tetraxetan (SSO110) in sufferers with ES-SCLC. The fundamental goal of the research is to ascertain a advisable Phase 2 dose and schedule.
‘Theranostics’ is the strategy of utilizing two paired medicine – the primary, a diagnostic agent to establish cells which exhibit a specific biomarker; and the second, a therapeutic drug, to behave on these cells. Both the diagnostic agent and therapeutic drug comprise Ariceum’s proprietary peptide satoreotide, a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SST2), a cell floor protein usually overexpressed in sure cancers together with small cell lung most cancers (SCLC).
The research, entitled LuSato-1 research, contains sufferers with ES-SCLC who will every obtain an infusion containing the diagnostic imaging agent, somatostatin receptor antagonist earlier than present process a positron emission tomography (PET) scan. This will decide if a affected person’s tumours categorical the SST2. Patients recognized with confirmed SST2 expression will obtain escalating doses of satoreotide, along with the immunotherapy atezolizumab, a PD-L1 checkpoint inhibitor, through the upkeep part of their therapy till a advisable part 2 dose will be outlined. Additional sufferers could also be enrolled in an growth cohort. Further particulars on the research will be discovered on Australian Clinical Trials, below identifier Ariceum SSO11O-01.
Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, mentioned: “The initiation of this Phase Ib research is a vital milestone reached by the Company in shut collaboration with our companions in Australia and Europe. We imagine that our lead focused systemic radiopharmaceutical product satoreotide has the potential to exhibit constructive leads to sufferers with intensive stage small cell lung most cancers. Theranostics holds nice hope as a extremely focused type of most cancers remedy, utilizing a ‘search and destroy’ strategy to hunt out tumours whereas sparing wholesome tissue.”
Germo Gericke, Chief Medical Officer of Ariceum Therapeutics, mentioned: “Although immune checkpoint blockade has improved the therapy of ES-SCLC, illness recurrence usually happens early within the upkeep part. Adding focused radiotherapy with satoreotide to immune checkpoint blockade within the upkeep setting holds the promise to enhance the therapeutic impact of the upkeep remedy.”
An Abstract on the LuSato-1 research will likely be introduced on the European Association of Nuclear Medicine Congress 2023 (EANM 2023) in Vienna, Austria, on 10th September 2023. Presentation particulars under.
Abstract OP-230
Top Rated Oral Presentations (TROP) Session: Oncology & Theranostics Committee
Session: 606 – Neuroendocrine Tumours Treatment
Abstract title: A part I theranostic research evaluating the protection and tolerability of 177Lu-satoreotide tetraxetan with 68Ga-satoreotide trizoxetan companion imaging in contributors with extensive-stage small-cell lung most cancers (ES-SCLC) on atezolizumab upkeep remedy
Authors: L. Emmett, J. Cardaci, Ok. O’Byrne, S. Arulananda, A. Prawira, B. Pais, M. Crumbaker, N. Lenzo
Date & Time: 10 September, 4:45-6:15pm CEST
Notes to Editors
About Ariceum Therapeutics
Ariceum Therapeutics (Ariceum) is a personal, scientific stage radiopharmaceutical firm centered on the prognosis and precision therapy of sure neuroendocrine and different aggressive, hard-to-treat cancers. The title Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium have been large contributions to discovering therapies for most cancers.
Ariceum’s lead focused systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (“satoreotide”), is an antagonist of the somatostatin sort 2 (SST2) receptor which is overexpressed in neuroendocrine tumours (NETs) and a few aggressive cancers akin to small cell lung most cancers (SCLC), all of which have few therapy choices and poor prognosis. Satoreotide is being developed as a ‘theranostic’ pair for the mixed prognosis and focused radionuclide therapy of those tumours.
Ariceum Therapeutics, launched in 2021, acquired all rights from Ipsen. Ipsen stays a shareholder within the Company. Ariceum is headquartered in Berlin, with operations in Germany, Australia, United Kingdom, United States of America and Switzerland and actions presently throughout the globe.
Ariceum is led by a extremely skilled administration group and supported by specialist buyers together with EQT Life Sciences (previously LSP), HealthCap, Pureos Bioventures, Andera Partners and Earlybird Venture Capital. For additional data, please go to www.ariceum-therapeutics.com
View unique content material:https://www.prnewswire.com/news-releases/ariceum-therapeutics-doses-first-patient-with-its-first-in-class-targeted-radiopharmaceutical-drug-satoreotide-in-its-phase-ib-study-in-small-cell-lung-cancer-301919787.html
SOURCE Ariceum Therapeutics
